Pinpointing a Factor in Myeloma Bone Disease.
A recent study implicates thymidine phosphorylase in myeloma-induced bone disease and suggests that inhibiting the enzyme may be a viable therapeutic option. Thymidine phosphorylase provokes osteolytic lesions by disrupting the balance between bone resorption and formation, shifting it toward a net loss of bone tissue.